StonvexLoading…
StonvexStonvexStonvexCore line items from NRDS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $836.60M | $687.60M | $599.40M | $538.90M |
Operating Income | $65.20M | $9.40M | $3.60M | $-19.00M |
Net Income | $48.70M | $30.40M | $-11.80M | $-10.20M |
EPS (Diluted) | $0.64 | $0.38 | $-0.15 | $-0.14 |
Total Assets | $461.10M | $437.60M | $418.60M | $425.70M |
Total Liabilities | $86.60M | $73.40M | $51.70M | $84.00M |
Cash & Equivalents | $98.30M | $66.30M | $100.40M | $83.90M |
Free Cash Flow OCF − CapEx | $130.30M | $71.20M | $71.40M | $20.40M |
Shares Outstanding | 71.29M | 74.11M | 76.94M | 75.12M |